StockNews.AI

*CORRECTION*INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Inovio Pharmaceuticals, Inc. - INO

StockNews.AI • 4 hours

INO
High Materiality8/10

Information

NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves...

Original source

AI Summary

Pomerantz LLP is investigating Inovio Pharmaceuticals for possible securities fraud related to INO-3107's FDA application. Following the FDA's decision to reject accelerated approval, Inovio's shares fell sharply, raising concerns among investors.

Sentiment Rationale

The significant stock drop due to the FDA's rejection of accelerated approval indicates severe market concern. Historical instances, such as similar FDA rejections leading to class actions, have often resulted in prolonged share price declines.

Trading Thesis

INO may face further downside in the near term due to legal risks and regulatory challenges.

Market-Moving

  • Potential class action lawsuits could create additional financial pressure for Inovio.
  • Inovio's ongoing FDA discussions may create volatility in stock price.
  • Regulatory scrutiny over past disclosures could impact investor sentiment significantly.

Key Facts

  • Pomerantz LLP is investigating Inovio for potential securities fraud.
  • The FDA accepted Inovio's BLA for INO-3107 but rejected accelerated approval.
  • Inovio's stock dropped 24.45% after the FDA announcement.
  • Investors can join a class action over allegations against Inovio's management.
  • Inovio plans to meet with the FDA to discuss accelerated approval options.

Companies Mentioned

  • Inovio Pharmaceuticals, Inc. (INO): Facing legal challenges which may impact stock price and investor confidence.
  • Pomerantz LLP: Not directly traded, but their investigation may lead to significant outcomes for INO investors.

Corporate Developments

This fits into the 'Corporate Developments' category due to serious allegations of securities fraud and ongoing FDA regulatory engagements impacting investor confidence and stock valuation.

Pomerantz Law Firm Investigates Potential Claims Against Inovio Pharmaceuticals, Inc. (NASDAQ: INO)

Overview of the Investigation

On January 13, 2026, Pomerantz LLP announced it is investigating claims on behalf of investors in Inovio Pharmaceuticals, Inc. (NASDAQ: INO). This inquiry aims to determine whether Inovio and some of its officers and directors have engaged in securities fraud or other illegal business practices. Investors interested in participating in the investigation are encouraged to reach out to Danielle Peyton at newaction@pomlaw.com or call 646-581-9980, ext. 7980.

Recent Developments Impacting INO

On December 29, 2025, the U.S. Food and Drug Administration (FDA) accepted Inovio’s Biologics License Application (BLA) for INO-3107, a proposed treatment for recurrent respiratory papillomatosis. However, the FDA indicated that Inovio did not provide sufficient information to justify eligibility for accelerated approval, despite the company's initial filing under that pathway.

  • Inovio does not currently plan to pursue approval under the standard review timeline.
  • The company intends to request a meeting with the FDA to discuss opportunities for accelerated approval.

This announcement had a significant impact on Inovio's stock performance, with shares dropping by $0.56 or 24.45%, bringing the closing price down to $1.73 per share on the reporting date.

Pomerantz LLP: A Trusted Advocate

Pomerantz LLP is a prominent law firm specializing in corporate, securities, and antitrust class litigation. Founded over 85 years ago by Abraham L. Pomerantz, known as the dean of the class action bar, the firm has built a solid reputation for advocating for victims of securities fraud and corporate misconduct. Pomerantz has recovered substantial damages on behalf of class members.

The firm operates in major cities, including New York, Chicago, and Los Angeles, providing extensive resources to fight for investors' rights.

Contact Information

For more information regarding this investigation or to participate, investors can contact:

Attorney advertising. Prior results do not guarantee similar outcomes.

Related News